NCT05544266|RecruitingDMC
Rare and Atypical Diabetes Network
RADIANT
Loading search results
RADIANT
Sponsor study identifier
Secondary identifiers
NIH
NIH
observational
2,000
1 country
13
Study Start
September 30, 2020
Actual (reported)Primary Completion
September 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
September 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 30, 2020
Actual (reported)August 23, 2022
Actual (reported)September 16, 2022
Actual (reported)September 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
September 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Phenotypic and genotypic characterization of previously unknown forms of diabetes using Whole Genome Sequencing (WGS), and deeper phenotyping methods
Deeper phenotyping methods include both clinical and laboratory assessments. Clinical data includes anthropometric and biometric data, medical histories, and standard questionnaires (ASA24, PROMIS, environmental exposures depression and anxiety). Laboratory data includes WGS, transcriptomics, metabolomics, mitochondrial sequencing, Oral Glucose Tolerance Test (OGTT), and Islet autoantibodies. Clustering methods will be used to define cohorts of similar diabetes genotypes and phenotypes based on this data.
Through study completion, an average of 3 years.
Probands and family members will be screened for evaluation of suspected atypical diabetes of unknown origin. Among the pool of evaluated individuals, those found to have a known form of diabetes will be excluded from further study. The remaining participants will be prioritized for genetic/genomic analysis and further testing.
University of Colorado- Denver
Aurora, Colorado, 80045, United States
University of Chicago
Chicago, Illinois, 60637, United States
RADIANT Study Group. The Rare and Atypical Diabetes Network (RADIANT) Study: Design and Early Results. Diabetes Care. 2023 Jun 1;46(6):1265-1270. doi: 10.2337/dc22-2440.
Whole Blood Serum Plasma DNA RNA Urine Peripheral Blood Monocytes (PBMCs)
Jeffrey Krischer, PhD
University of South Florida
First Submitted
August 23, 2022
First Posted
September 16, 2022
Study Start
September 30, 2020
Actual (reported)Primary Completion
September 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Analysis of Volatile Organic Compounds in Patients With Type 1 Diabetes in Induced Hypoglycaemia With a Breath Analyser
Contact the study team to confirm eligibility.
Indiana University
Indianapolis, Indiana, 46202, United States
University of Maryland
Baltimore, Maryland, 21201, United States
Massachusetts General Hospital (MGH)
Boston, Massachusetts, 02114, United States
University of Michigan
Ann Arbor, Michigan, 48109, United States
Washington University in St. Louis
St Louis, Missouri, 63110, United States
SUNY Downstate Health Sciences University
Brooklyn, New York, 11203, United States
Columbia University
New York, New York, 10032, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
Vanderbilt University
Nashville, Tennessee, 37232, United States
Baylor College of Medicine
Houston, Texas, 77030, United States
University of Washington
Seattle, Washington, 98109, United States
Study Completion
September 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 14, 2025
Record last verified: 2025-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: